Fennec Pharmaceuticals (STU:RV41) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Asset Impairment Charge?

Fennec Pharmaceuticals's Asset Impairment Charge for the three months ended in Mar. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Fennec Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Fennec Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Asset Impairment Charge Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Fennec Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Fennec Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Fennec Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (STU:RV41) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

FENC:USA FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines